4.6 Review

Migraine and its psychiatric comorbidities

Journal

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 87, Issue 7, Pages 741-749

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2015-312233

Keywords

-

Funding

  1. Alder
  2. Allergan
  3. CoLucid
  4. Electrocore
  5. eNeura
  6. Ethicon
  7. Merck
  8. Novartis
  9. Labrys
  10. Autonomic Technologies
  11. Boston Scientific
  12. Bristol Myers Squibb
  13. Dr Reddys
  14. Eli Lilly
  15. Endo Pharmaceuticals
  16. Informa
  17. Migraine Research Fund
  18. National Headache Foundation
  19. NIH
  20. Teva
  21. Vedanta
  22. Zogenix
  23. Supernus

Ask authors/readers for more resources

Migraine is a highly prevalent and disabling neurological disorder associated with a wide range of psychiatric comorbidities. In this manuscript, we provide an overview of the link between migraine and several comorbid psychiatric disorders, including depression, anxiety and post-traumatic stress disorder. We present data on psychiatric risk factors for migraine chronification. We discuss the evidence, theories and methods, such as brain functional imaging, to explain the pathophysiological links between migraine and psychiatric disorders. Finally, we provide an overview of the treatment considerations for treating migraine with psychiatric comorbidities. In conclusion, a review of the literature demonstrates the wide variety of psychiatric comorbidities with migraine. However, more research is needed to elucidate the neurocircuitry underlying the association between migraine and the comorbid psychiatric conditions and to determine the most effective treatment for migraine with psychiatric comorbidity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available